<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772209</url>
  </required_header>
  <id_info>
    <org_study_id>ZADH-1</org_study_id>
    <nct_id>NCT04772209</nct_id>
  </id_info>
  <brief_title>Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters</brief_title>
  <official_title>Comparison of Effectiveness and Complications of Heparin and Sodium Bicarbonate Catheter Lock Solutions in Non-Tunneled Hemodialysis Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zonguldak Ataturk State Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cumhuriyet University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sisli Hamidiye Etfal Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zonguldak Ataturk State Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our study, investigators will investigate the effectiveness and complications of two&#xD;
      catheter lock solutions one of which is the standard heparin routinely used in comparison to&#xD;
      Sodium bicarbonate. Both solutions were used but not compared head to head. Investigators aim&#xD;
      to compare both solutions in terms of catheter lumen patency and their effect on&#xD;
      catheter-related infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most important problem in patients with end-stage renal disease or patients with acute&#xD;
      renal failure needing urgent hemodialysis treatment is the lack of appropriate vascular&#xD;
      access. In acute situations, vascular access is usually provided by non-tunneled catheters.&#xD;
      Main problems with this temporaray vascular access is failure due to lumen thrombosis. anther&#xD;
      major problem is catheter related infection. In some patients, there is a handicap of using&#xD;
      heparin. In some situations, heparin is not preferred for use. In terms of the probable&#xD;
      shortage of resources and cost-effectiveness, Investigators aimed to compare head to head the&#xD;
      superiority and non-inferiority of each solution. Sodium bicarbonate was compared to the&#xD;
      isotonic solution and found to be effective for a short time. The main aim of this study is&#xD;
      to compare both classic Heparin and sodium bicarbonate in Femoral and Jugular catheters aimed&#xD;
      for dialysis. In both arms, the maximum patency and the observed side effects will be&#xD;
      recorded. The maximal time used will be recorded. statistical analysis will be planned to&#xD;
      compare the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bicarbonate vs Heparin group (femoral vs jugular catheter)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first catheter failure (day)</measure>
    <time_frame>6 months</time_frame>
    <description>The time from first sucessful dialysis session to the last one (in days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Duration of catheter usage (day)</measure>
    <time_frame>6 months</time_frame>
    <description>some patients need only 1-2 dialysis sessions while others may need too many sessions. In some cases a total of three dialysi sessions is whithin 3-4 days while others may need that number in wider range (e.g 10-14 days). Here both number and duraion effect is evaluated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with catheter occlusion</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases early catheter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with catheter related infection</measure>
    <time_frame>6 months</time_frame>
    <description>any catheter related infection(exit site, lumen inection etc) will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of catheter occlusion or failure</measure>
    <time_frame>6 months</time_frame>
    <description>catheteres occluded by thrombi will be documented</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Causes of premature catheter malfunction</measure>
    <time_frame>6 months</time_frame>
    <description>any catheter needing exchange prematurly will be be evaluated for mulfunction cause (etiher mechanical thromus or kink rtc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of dialysis sessions with active patent catheter usage</measure>
    <time_frame>6 months</time_frame>
    <description>In some cases intensive treatment is indicated. the effect of frequent usage of catheteres will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with venous thrombosis</measure>
    <time_frame>6 months</time_frame>
    <description>catheters especially femoral have a risk of venous thrombosis, any clincal sign of thrombosis will be recorded. In case of catheter removal doppler ultrasound will be documented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Catheter Blockage</condition>
  <condition>Catheter-Related Infections</condition>
  <condition>Dialysis Catheter; Thrombosis</condition>
  <condition>Catheter Infection</condition>
  <condition>Catheter Related Complication</condition>
  <condition>Catheter Dysfunction</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, the catheter lock solution is sodium bicarbonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.</description>
    <arm_group_label>Sodium bicarbonate Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.</description>
    <arm_group_label>Heparin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients over 18 years who assign consent will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients less than 18 years of age&#xD;
&#xD;
          -  Patients with active arterial or venous thrombosis problems&#xD;
&#xD;
          -  Thrombocytopenic patients&#xD;
&#xD;
          -  Patients with hypercoagulable states&#xD;
&#xD;
          -  Patients with contraindications to heparin usage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MAHMUD M ISLAM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zonguldak Ataturk State Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MAHMUD ISLAM, MD</last_name>
    <phone>00905556551458</phone>
    <email>drisleem@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yener koç, PHD</last_name>
    <phone>00905055618780</phone>
    <email>yenerkoc@cumhuriyet.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Şişli Etfal State Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>TN</state>
        <zip>34362</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer Sakaci, PHD</last_name>
      <email>sakacitamer@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>tamer sakaci</last_name>
      <email>sakacitamer@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cumhuriyet University Hospital</name>
      <address>
        <city>Sivas</city>
        <state>TN</state>
        <zip>34762</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YENER KOC, phd</last_name>
      <email>yenerkoc@cumhuriyet.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zonguldak ataturk state hospital</name>
      <address>
        <city>Zonguldak</city>
        <state>TN</state>
        <zip>67100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAHMUD ISLAM, MD</last_name>
      <email>drisleem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>BETUL TURKOGLU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>YENER KOC, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>TAMER SAKACI, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>El-Hennawy AS, Frolova E, Romney WA. Sodium bicarbonate catheter lock solution reduces hemodialysis catheter loss due to catheter-related thrombosis and blood stream infection: an open-label clinical trial. Nephrol Dial Transplant. 2019 Oct 1;34(10):1739-1745. doi: 10.1093/ndt/gfy388.</citation>
    <PMID>30668833</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zonguldak Ataturk State Hospital</investigator_affiliation>
    <investigator_full_name>mahmud islam</investigator_full_name>
    <investigator_title>Medical Director of Nephrology clinic</investigator_title>
  </responsible_party>
  <keyword>catheter lock solution</keyword>
  <keyword>sodium bicarbonate</keyword>
  <keyword>heparin</keyword>
  <keyword>Non-tunneled dialysis catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol and methods will be available in a paper intended for publication, any materials or data may be available on demand</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Starting in February 2021 ends in September 2021</ipd_time_frame>
    <ipd_access_criteria>The inquired information will be sent by e-mail</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

